Webinar Video | Life Sciences Session #1: What’s new in the parallel world of parallel trade?

Webinar Video | Life Sciences Session #1: What’s new in the parallel world of parallel trade?
November 24, 2020

In our first Life Sciences Session, our experts Philippe de Jong and Kirian Claeyé talk you through a number of recent decisions and developments in the field of parallel trade of pharmaceuticals, medical devices and plant protection products, including:

  • The rebranding of generics to original brand reference products
  • The impact of the falsified medicines framework on parallel trade
  • Further points of attention when verifying in light of the BMS conditions

Written by

  • Philippe de Jong

    Partner

  • Kirian Claeyé

    Counsel

Recommended articles

December 02, 2022

Are parallel importers necessarily allowed to rebox medicines in case of visible traces from ATDs? The CJEU says NO

Pharmaceutical companies are obliged to affix an anti-tampering device (‘ATD’) on prescription-only medicines to enable verification of whether a medicine’s packaging has been tampered with. Parallel importers argue that this results in an overarching objective necessity to ‘rebox’ such medicines.

Read on
November 24, 2022

Can parallel importers (re)brand generic medicines? The CJEU limits the ‘room for manoeuvre’

If a branded medicine and its generic version are put on the EEA market by economically-linked undertakings, is a parallel importer then allowed to rebrand and repackage the imported generic version as the branded reference medicine? After the Brussels Court of Appeal had referred questions on this issue for a preliminary ruling two years ago, the CJEU has now clarified the limits.

Read on
November 23, 2022

New rules on medical force majeure and the medical certificate

A new Act, which includes various provisions on incapacity for work, was published in the Belgian State Gazette on 18 November 2022.

Read on